Edition:
United States

Profile: Biocon Ltd (BION.BO)

BION.BO on Bombay Stock Exchange

243.10INR
6:28am EDT
Change (% chg)

Rs-2.70 (-1.10%)
Prev Close
Rs245.80
Open
Rs247.20
Day's High
Rs247.65
Day's Low
Rs238.90
Volume
234,290
Avg. Vol
225,139
52-wk High
Rs359.17
52-wk Low
Rs238.90

Biocon Limited is a biopharmaceutical company. The Company focuses to reduce therapy costs of chronic diseases like autoimmune, diabetes, and cancer. Through its products and research services it is enabling access to affordable healthcare for patients, partners and healthcare systems across the globe. The Company has developed and taken a range of Novel Biologics, Biosimilars, differentiated Small Molecules and affordable Recombinant Human Insulin and Analogs from Lab to Market. The Company’s brands include INSUGEN (rh-insulin), BASALOG (Glargine), CANMAb (Trastuzumab), BIOMAb-EGFR (Nimotuzumab) and ALZUMAb (Itolizumab), an anti-CD6 monoclonal antibody. It has a pipeline of Biosimilars and Novel Biologics at various stages of development, including Insulin Tregopil, an oral insulin analog.

Company Address

Biocon Ltd

20th KM, Hosur Road, Electronics
BANGALORE     560100
P: +9180.28082808
F: +9180.28523423

Company Web Links